Prostate Cancer

The American Society for Radiation Oncology’s board of directors recently approved a statement regarding the use of proton beam therapy for prostate cancer, presumably due to recent reports suggesting the treatment provides little long-term benefit over traditional radiation despite its higher cost.

Anticoagulation while on docetaxel (Taxotere) chemotherapy appears to be an independent predictor of survival in men with metastatic castration-resistant prostate cancer (mCRPC).

Focal laser ablation is safe and can be performed without the troubling complications associated with more aggressive therapies for low-risk prostate cancer, results of a small phase I study indicate.

More stringent criteria may be needed for African-American men with prostate cancer when considering active surveillance for their disease, new research from The Cancer Institute of New Jersey, New Brunswick suggests.

Patients with high-risk prostate cancer who undergo 18 months of androgen blockade live as long as those who have 36 months of treatment, according to results of a recent phase III study.

Nearly three-quarters of patients undergoing radiation therapy for prostate cancer had no evidence of the disease at 25 years’ follow-up, the authors of a study from Radiotherapy Clinics of Georgia, Atlanta recently reported.

The AUA has released a new white paper providing recommendations for optimal prostate biopsy sampling, labeling, and processing.

The incidence of secondary malignancies following prostate cancer therapy is similarly uncommon whether the treatment is surgery, brachytherapy, or external beam therapy.

Advanced age does not influence postoperative continence or cancer-specific survival after radical prostatectomy, according to a recent study.

Urologists share how confident they feel about active surveillance for low-risk prostate cancer.

A new study suggests that exercise may reduce Caucasian men's risk of developing prostate cancer.

Many synthetic chemicals, untested for their disrupting effects on the hormone system, may have significant health implications, including contributing to the development of prostate cancer in men and undescended testes in young males.

Three "field effect" epigenetic biomarkers were found to be more prevalent in histologically benign biopsy cores from prostate cancer patients diagnosed with Gleason score 7 prostate cancer than in those with low-volume Gleason 6 disease, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.

A large study presented at the Genitourinary Cancers Symposium in Orlando, FL has confirmed that prostate cancer detection rates are enhanced when 10 to 12 specimens are obtained during biopsy.

Patients with high-risk prostate cancer who received 18 months of hormone therapy lived as long as patients treated for 36 months, Canadian researchers report.

The FDA has granted priority review to the new drug application filed for radium-223 dichloride, an investigational compound under review for the treatment of patients with castration-resistant prostate cancer who have bone metastases.

Nearly a quarter of family physicians order PSA tests without discussing the test with patients, according to a recent study.

This month's round-up of new products includes CIVCO patient drapes, MediSafe Projects' medication alert app, a direct purchase program for Zoladex, and GAMMEX non-latex-sensitive surgical gloves.

New research shows that men with a high risk of bone fracture who are undergoing long-term androgen deprivation therapy (ADT) for prostate cancer have a higher fracture incidence following treatment completion.

More than 3% of prostate biopsies are subject to medical errors or contamination, a recent study found.

In May 2012, the United States Preventive Services Task Force recommended against PSA testing in all men based upon a flawed analysis that overestimated the harms and underestimated the benefits of testing.

This special installment of "Hands On" is presented in a point-counterpoint format, with two leading experts discussing open versus. robot-assisted radical prostatectomy.